Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | June 29, 2026

Jun 29, 2026

•

3 min read

Biotech & Pharma Updates | June 29, 2026

🧬 Ipsen to acquire Kartos Therapeutics for up to $1.75B, adding myelofibrosis candidate navtemadlin to oncology pipeline, Viridian Therapeutics' Lumvoa (veligrotug-vvze) wins FDA approval for thyroid eye disease across active and chronic disease, Zymeworks to acquire Theravance for $929M, gaining approved COPD drug Yupelri and lucrative royalty deals

Christian Cuchapin, +1

Biotech & Pharma Updates | June 26, 2026

Jun 26, 2026

•

3 min read

Biotech & Pharma Updates | June 26, 2026

🧬 FDA accepts Replimune's RP1 resubmission for advanced melanoma, sets early August decision after two prior rejections, Bayer wins Supreme Court ruling overturning $1.25M Roundup cancer verdict, shares surge 19%, Amgen's Tavneos loses EU endorsement over data integrity concerns ahead of FDA hearing

Christian Cuchapin, +1

Biotech & Pharma Updates | June 25, 2026

Jun 25, 2026

•

3 min read

Biotech & Pharma Updates | June 25, 2026

🧬 Merck KGaA to acquire Bio-Techne Corporation for $11.3B in largest deal since 2015 Sigma-Aldrich purchase, FDA approves Gilead's Trodelvy (sacituzumab govitecan) and Merck & Co.'s Keytruda combo for first-line triple-negative breast cancer, Oblenio Bio raises $62M Series B, advancing tri-specific autoimmune T-cell engager to trials

Christian Cuchapin, +1

Biotech & Pharma Updates | June 24, 2026

Jun 24, 2026

•

3 min read

Biotech & Pharma Updates | June 24, 2026

🧬 Serapha Bio goes public via reverse merger with Boundless Bio, raising $230M and licensing gene editor from China, Ollin Biosciences raises $330M Series B to advance Vabysmo-challenging eye disease therapy, Eli Lilly expands partnership with Abbisko Therapeutics on precision oncology therapies, deal worth up to $1.9B

Christian Cuchapin, +1

Biotech & Pharma Updates | June 23, 2026

Jun 23, 2026

•

3 min read

Biotech & Pharma Updates | June 23, 2026

🧬 CARsgen Therapeutics' (satricabtagene autoleucel) wins NMPA approval targeting Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma after Ph2 success, Eli Lilly's tirzepatide leads obesity-driven forecast of $2T global drug sales by 2032, HHS, FDA launch "unprecedented" initiative to cut clinical trial timelines, restore U.S. drug development leadership

Christian Cuchapin, +1

Biotech & Pharma Updates | June 22, 2026

Jun 22, 2026

•

4 min read

Biotech & Pharma Updates | June 22, 2026

🧬 AbbVie acquires Apogee Therapeutics for $10.9B to bolster immunology portfolio and challenge Dupixent, FDA advisory panel unanimously backs Moderna's (mRNA-1010) mRNA influenza vaccine for adults aged 50 and older, Definium Therapeutics' DT120 ODT (lysergic acid diethylamide) meets all Ph3 endpoints for major depressive disorder

Christian Cuchapin, +1

Biotech & Pharma Updates | June 18, 2026

Jun 18, 2026

•

3 min read

Biotech & Pharma Updates | June 18, 2026

🧬 GSK, Spero Therapeutics' Utebzi (tebipenem pivoxil) wins FDA approval for complicated urinary tract infections following Ph3 success, Kardigan raises $400M IPO, advancing cardiovascular drug trio including dilated cardiomyopathy treatment, Biogen acquires RayThera for $1B, adding preclinical anti-inflammatory small molecule pipeline candidates

Christian Cuchapin, +1

Biotech & Pharma Updates | June 17, 2026

Jun 17, 2026

•

3 min read

Biotech & Pharma Updates | June 17, 2026

🧬 Moderna's mRNA flu shot mFlusiva gets favorable FDA review ahead of critical advisory committee vote, Eli Lilly to acquire 4E Therapeutics, expanding non-opioid pain pipeline with MNK inhibitor treatments, PwC declares biopharma M&A ecosystem fully recovered, predicting continued precision-science dealmaking through year-end

Christian Cuchapin, +1

Biotech & Pharma Updates | June 16, 2026

Jun 16, 2026

•

3 min read

Biotech & Pharma Updates | June 16, 2026

🧬 Intellia Therapeutics' (lonvoguran ziclumeran) achieves 89% attack reduction in Ph3 hereditary angioedema study, Germany drops variable drug discount plans after Boehringer Ingelheim and Eli Lilly withdraw investments, Recipharm channels multi-million-dollar U.S. manufacturing upgrade to meet surging domestic biologics demand

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | June 29, 2026

Biotech & Pharma Updates | June 26, 2026

Biotech & Pharma Updates | June 25, 2026

Biotech & Pharma Updates | June 24, 2026

Biotech & Pharma Updates | June 23, 2026

Biotech & Pharma Updates | June 22, 2026

Biotech & Pharma Updates | June 18, 2026

Biotech & Pharma Updates | June 17, 2026

Biotech & Pharma Updates | June 16, 2026

TLDR Biotech

FAQ

Media Partners